The novel inosine analogue, INO-2002, protects against diabetes development in multiple low-dose streptozotocin and non-obese diabetic mouse models of type I diabetes

Journal of Endocrinology

Volumn 198, Issue 3, 2008, Pages 581-589

  Mabley, Jon G ^a   Pacher, Pal ^b   Murthy, Kanneganti G K ^c   Williams, William ^c   Southan, Garry J ^c   Salzman, Andrew L ^c   Szabo, Csaba ^d  

^a UNIVERSITY OF BRIGHTON   (United Kingdom)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c INOTEK CORPORATION   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CYTOKINE; GLUCOSE; INO 2002; INOSINE; INOSINE DERIVATIVE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS; PRIORITY JOURNAL; STREPTOZOCIN DIABETES;

5'-NUCLEOTIDASE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HYPERGLYCEMIA; INOSINE; INOSINE MONOPHOSPHATE; INSULIN; INSULIN-SECRETING CELLS; INTERLEUKIN-12; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, OBESE; PANCREAS; PENTOSYLTRANSFERASES; STREPTOZOCIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 53349173692     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-07-0511     Document Type: Article

References (50)

1. Allison AC & Eugui EM 2000 Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47 85-118.
2. Ames BN, Cathcart R, Schwiers E & Hochstein P 1981 Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. PNAS 78 6858-6862.
3. Atkinson MA & Leiter EH 1999 The NOD mouse model of type 1 diabetes: as good as it gets? Nature Medicine 5 601-604.
4. Bach J-F 1994 Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrine Reviews 15 516-542.
5. Becker BF, Reinholz N, Ozcelik T, Leipert B & Gerlach E 1989 Uric acid as radical scavenger and antioxidant in the heart. Pflugers Archiv 415 127-135.
6. Bradford MM 1976 A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72 248-254.
7. Cameron MJ, Arreaza GA, Grattan M, Meagher C, Sharif S, Burdick MD, Strieter RM, Cook DN & Delovitch TL 2000 Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes. Journal of Immunology 165 1102-1110.
8. Campoli-Richards DM, Sorkin EM & Heel RC 1986 Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 32 383-424.
9. Chatenoud L, Primo, J & Bach JF 1997 CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. Journal of Immunology 158 2947-2954.
10. Darlington DN & Gann DS 2005 Inosine infusion prevents mortality in endotoxic shock. Journal of Trauma 59 1432-1435 (discussion 1435).
11. Eizirik DL & Darville MI 2001 β-cell apoptosis and defense mechanisms: lessons from type 1 diabetes. Diabetes 50 (Suppl 1) S64-S69.
12. Garcia Soriano F, Liaudet L, Marton A, Hasko G, Batista Lorigados C, Deitch EA & Szabo C 2001 Inosine improves gut permeability and vascular reactivity in endotoxic shock. Critical Care Medicine 29 703-708.
13. Harlan DM, Barnett MA, Abe R, Pechhold K, Patterson NB, Gray GS & June CH 1995 Very-low-dose streptozotocin induces diabetes in insulin promoter-mB7-1 transgenic mice. Diabetes 44 816-823.
14. Hasko G, Kuhel DG, Nemeth ZH, Mabley JG, Stachlewitz RF, Virag L, Lohinai Z, Southan GJ, Salzman AL & Szabo C 2000 Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. Journal of Immunology 164 1013-1019.
15. Hasko G, Sitkovsky MV & Szabo C 2004 Immunomodulatory and neuroprotective effects of inosine. Trends in Pharmacological Sciences 25 152-157.
16. Lakey JR, Suarez-Pinzon WL, Strynadka K, Korbutt GS, Rajotte RV, Mabley JG, Szabo C & Rabinovitch A 2001 Peroxynitrite is a mediator of cytokine-induced destruction of human pancreatic islet β-cells. Laboratory Investigation 81 1683-1692.
17. Li P, Ogino K, Hoshikawa Y, Morisaki H, Cheng J, Toyama K, Morisaki T, Hashimoto K, Ninomiya H, Tomikura-Shimoyama Y et al. 2007 Remote reperfusion lung injury is associated with AMP deaminase 3 activation and attenuated by inosine monophosphate. Circulation Journal 71 591-596.
18. Liaudet L, Mabley JG, Soriano FG, Pacher F, Marton A, Hasko G & Szabo C 2001 Inosine reduces systemic inflammation and improves survival in septic shock induced by cecal ligation and puncture. American Journal of Respiratory and Critical Care Medicine 164 1213-1220.
19. Liaudet L, Mabley JG, Pacher P, Virag L, Soriano FG, Marton A, Hasko G, Deitch EA & Szabo C 2002 Inosine exerts a broad range of antiinflammatory effects in a murine model of acute lung injury. Annals of Surgery 235 568-578.
20. Like AA & Rossini AA 1976 Streptozotocin-induced pancreatic insubtis: new model of diabetes mellitus. Science 193 415-417.
21. Mabley JG, Jagtap F, Perretti M, Getting SJ, Salzman AL, Virag L, Szabo E, Soriano FG, Liaudet L, Abdelkarim GE et al. 2001a Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase. Inflammation Research 50 561-569.
22. Mabley JG, Suarez-Pinzon WL, Hasko G, Salzman AL, Rabinovitch A, Kun E & Szabo C 2001b Inhibition of poly (ADP-ribose) synthetase by gene disruption or inhibition with 5-poly-6-amino-1,2-benzopyrone protects mice from multiple-low-dose-streptozotocin-induced diabetes. British Journal of Pharmacology 133 909-919.
23. Mabley JG, Virag L & Szabo C 2002 Role of poly (ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and diabetic vascular dysfunction. In PARP as a Therapeutic Target, pp 277-319. Ed. J Zhang. London: CRC Press.
24. Mabley JG, Pacher P, Liaudet L, Soriano FG, Hasko G, Marton A, Szabo C & Salzman AL 2003a Inosine reduces inflammation and improves survival in a murine model of colitis. American Journal of Physiology. Gastrointestinal and Liver Physiology 284 G138-G144.
25. Mabley JG, Ribinovitch A, Suarez-Pinzon W, Hasko G, Pacher P, Power R, Southan G, Salzman A & Szabo C 2003b Inosine protects against the development of diabetes in multiple-low-close streptozotocin and nonobese diabetic mouse models of type 1 diabetes. Molecular Medicine 9 96-104.
26. Mabley JG, Southan GJ, Salzman AL & Szabo C 2004 The combined inducible nitric oxide synthase inhibitor and free radical scavenger guanidnioethyldasulfide prevents multiple low-dose streptozotocin-induced diabetes in vivo and interleukin-1β-induced suppression of islet insulin secretion in vitro. Pancreas 28 E39-E44.
27. Mabley JG, Pacher P, Deb A, Wallace R, Elder RH & Szabo C 2005 Potential role for 8-oxoguanine DNA glycosylase in regulating inflammation. FASEB Journal 19 290-292.
28. Maksimovic-Ivanic D, Trajkovic V, Miljkovic DJ, Mostarica Stojkovic M & Stosic-Grujicic S 2002 Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil. Clinical and Experimental Immunology 129 214-223.
29. Martin AP, Alexander-Brett JM, Canasto-Chibuque C, Garin A, Bromberg JS, Fremont DH & Lira SA 2007 The chemokine binding protein M3 prevents diabetes induced by multiple low doses of streptozotocin. Journal of Immunology 178 4623-4631.
30. Marton A, Pacher P, Murthy KG, Nemeth ZH, Hasko G & Szabo C 2001 Anti-inflammatory effects of inosine in human monocytes, neutrophils and epithelial cells in vitro. International Journal of Molecular Medicine 8 617-621.
31. Nemeth ZH, Bleich D, Csoka B, Pacher P, Mabley JG, Himer L, Vizi ES, Deitch EA, Szabo C, Cronstein BN et al. 2007 Adenosine receptor activation ameliorates type 1 diabetes. FASEB Journal 21 2379-2388.
32. Ohta A & Sirkovsky M 2001 Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414 916-920.
33. Qiu FH, Wada K, Stahl GL & Serhan CN 2000 IMP and AMP deaminase in reperfusion injury down-regulates neutrophil recruitment. PNAS 97 4267-4272.
34. Rabinovitch A 1998 An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes/Metabolism Reviews 14 129-151.
35. Rabinovitch A & Suarez-Pinzon WL 1998 Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochemical Pharmacology 55 1139-1149.
36. Rabinovitch A, Suarez-Pinzon WL & Sorensen O 1996 Interleukin 12 mRNA expression in islets correlates with beta-cell destruction in NOD mice. Journal of Autoimmunity 9 645-651.
37. Rossini AA, Williams RM, Appel MC & Like AA 1978 Complete protection from low-dose streptozotocin-induced diabetes in mice. Nature 276 182-184.
38. Rothe H, O'Hara RM Jr, Martin S & Kolb H 1997 Suppression of cyclophosphamide induced diabetes development and pancreatic Th1 reactivity in NOD mice treated with the interleukin (IL)- 12 antagonist IL-12(p40)2. Diabetologia 40 641-646.
39. Ryu S, Kodama S, Ryu. K, Schoenfeld DA & Faustman DL 2001 Reversal of established autoimmune diabetes by restoration of endogenous β-cell function. Journal of Clinical Investigation 108 63-72.
40. Schneider S & Klein HH 2005 Inosine improves islet xenograft survival in immunocompetent diabetic mice. European Journal of Medical Research 10 283-286.
41. Sia C 2005 Imbalance in th cell polarization and its relevance in type 1 diabetes mellitus. Review of Diabetic Studies 2 182-186.
42. Stosic-Grujicic S, Maksimovic-Ivanic D, Miljkovic D, Tragkovic V, Lukic M & Mostarica Stojkovic M 2002 Inhibition of autoimmune diabetes by mycophenolate mofetil is associated with down-regulation of TH1 cytokine-induced apoptosis in the target tissue. Transplantation Proceedings 34 2955-2957.
43. Suarez-Pinzon WL, Mabley JG, Strynadka K, Power RF, Szabo C & Rabinovitch A 2001 An inhibitor of inducible nitric oxide synthase and scavenger of peroxynitrite prevents diabetes development in nod mice. Journal of Autoimmunity 16 449-455.
44. Suarez-Pinzon WL, Mabley JG, Power R, Szabo C & Rabinovitch A 2003 Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes. Diabetes 52 1683-1688.
45. Szabó C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virag L, Soriano FG, Van Duzer JH, Williams W, Salzman AL et al. 2002 Part 1: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Molecular Medicine 8 571-580.
46. Szabo G, Stumpf N, Radovits T, Sonnenberg K, Gero D, Hagl S, Szabo C & Bahrle S 2006 Effects of mosine on reperfusion injury after heart transplantation. European Journal of Cardio- Thoracic Surgery 30 96-102.
47. Szkudelski T 2001 The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiological Research 50 537-546.
48. Virag L & Szabo C 2001 Purities inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death. FASEB Journal 15 99-107.
49. Ward SG, Bacon K & Westwick J 1998 Chemokines and T lymphocytes: more than an attraction. Immunity 9 1-11.
50. Wybran J, Famaey JP & Appelboom T 1981 Inosiplex: a novel treatment in rheumatoid arthritis? Journal of Rheumatology 8 643-646.